When 'Make in India' meets global ambition!

 Budget 2026: India's Bold Vision for Pharmaceutical & Healthcare Leadership

India's Budget 2026 charts an ambitious roadmap to transform the nation into a global pharmaceutical and healthcare powerhouse, and the implications for our industry are profound.

At the heart of this transformation is the Biopharma Shakti Initiative, a ₹10,000 crore investment over five years designed to establish India as a global biopharma manufacturing hub. This isn't just about infrastructure, it's about addressing India's rising burden of non-communicable diseases like diabetes, cancer, and autoimmune disorders while positioning Indian manufacturers as reliable global suppliers of biologics and biosimilars.

The government is backing this vision with substantial talent development. Three new National Institutes of Pharmaceutical Education and Research (NIPERs) will be established alongside upgrades to seven existing ones, while a network of 1,000 accredited clinical trial sites will be created across India. The commitment extends to training 1 lakh allied health professionals and 1.5 lakh multiskilled caregivers over the next five years, ensuring our industry has the skilled workforce it needs to scale.

Regulatory reforms at CDSCO are equally critical. By aligning with global standards through dedicated scientific review cadres and specialist personnel, India is not just reducing approval timeframes it's enhancing its credibility as a regulatory authority that global partners can trust. When combined with the recently signed India-EU FTA that eliminates up to 11% customs duties on pharmaceuticals and unlocks access to an over €500 billion EU market, the ecosystem for Indian CDMO/CMO units becomes remarkably competitive.

Trade facilitation is getting a major boost too. The Authorized Economic Operator (AEO) program now enables  certified entities to benefit from same-day clearance, deferred duty payments, and direct port delivery, translating into substantial time and cost savings. For pharmaceutical manufacturers scaling operations to serve both domestic and international markets, this streamlined infrastructure is game-changing.

The five regional medical hubs announced for medical tourism will fundamentally reshape our diagnostics and preventive healthcare landscape. These public-private partnerships will feature AYUSH centres, advanced diagnostic infrastructure, and post-care rehabilitation facilities, creating opportunities across the healthcare value chain while attracting international patients seeking quality care at competitive costs.

On the affordability front, the exemption of basic customs duty on 17 cancer medicines and inclusion of 7 additional rare diseases for duty exemptions on personal drug imports reflects the government's commitment to accessible healthcare. These aren't just policy measures they're lifelines for patients and families facing critical health challenges.

What this means for Indian pharma: We're positioned at a unique intersection of traditional medicine excellence, cutting-edge biopharmaceutical innovation, world-class medical tourism infrastructure, and streamlined regulatory and trade mechanisms. For CDMO/CMO units, contract manufacturers, and healthcare service providers, the convergence of enhanced talent pools, robust R&D infrastructure, and improved trade facilitation creates unprecedented growth potential.